EUVIMEDEUVIMED entdecken
Crossref

Utilization and Tolerability of Alternative Infliximab and Biosimilar Dosing Strategies Among Adult Patients in the Home Infusion Setting: A Retrospective Study

Natalie Garcia, Andrew Chin, Cara Bivona, Maria Giannakos, Christopher Roy, Michelle Sahlani, David Shepherd

Infusion Journal · 01.03.2026 · 5 (1) · 5-10

DOI: 10.70776/dges5928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infusion Journal, online erschienen am 01.03.2026. Verfasst von Natalie Garcia und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infliximab and its biosimilars are used to treat several chronic inflammatory conditions. While standard dosing is effective, patients can experience loss of response and require dose escalation, shortening dose intervals or higher doses.

Objective

To describe the use and tolerability of alternative infliximab dosing strategies in the home infusion setting.

Methods

This retrospective, multi-site observational study included adults (≥18 years) who received intravenous infliximab and its biosimilars infliximab-abda, infliximab-axxq, and infliximab-dyyb, over 2 years. Data on demographics, dosing, and adverse drug reactions (ADRs) were collected from the electronic medical records and analyzed descriptively.

Results

A total of 202 patients from 92 sites in the U.S. were included. Among those receiving alternative regimens, 22.8% received doubled dosing (10 mg/kg) and 8.9% received shortened intervals (every 4 weeks). ADRs occurred more often with the doubled dose group compared to shortened intervals (Difference 13.9%). Of patients who reported ADRs, 84.1% discontinued infliximab and 45% switched to another biologic. The most common ADRs reported were flushing, dyspnea, and chest discomfort, with 76.3% of ADRs managed in the home.

Conclusions

Alternative dosing strategies for dose escalation are utilized in the home infusion setting, but doubling the dose is associated with higher rates of reported ADRs compared to shortened intervals. These results highlight the importance of close monitoring and the need for future research to define optimal dosing approaches, balancing efficacy, safety, and practical challenges in home infusion care.

Zitieren

APA

Garcia, N., Chin, A., Bivona, C., Giannakos, M., Roy, C., Sahlani, M., & Shepherd, D. (2026). Utilization and Tolerability of Alternative Infliximab and Biosimilar Dosing Strategies Among Adult Patients in the Home Infusion Setting: A Retrospective Study. Infusion Journal, 5(1), 5-10. https://doi.org/10.70776/dges5928

Vancouver

Garcia N, Chin A, Bivona C, Giannakos M, Roy C, Sahlani M, et al. Utilization and Tolerability of Alternative Infliximab and Biosimilar Dosing Strategies Among Adult Patients in the Home Infusion Setting: A Retrospective Study. Infusion Journal. 2026;5(1):5-10. doi:10.70776/dges5928

BibTeX
@article{Garcia2026,
  author = {Garcia, Natalie and Chin, Andrew and Bivona, Cara and Giannakos, Maria and Roy, Christopher and Sahlani, Michelle and Shepherd, David},
  title = {Utilization and Tolerability of Alternative Infliximab and Biosimilar Dosing Strategies Among Adult Patients in the Home Infusion Setting: A Retrospective Study},
  journal = {Infusion Journal},
  year = {2026},
  volume = {5},
  number = {1},
  pages = {5--10},
  doi = {10.70776/dges5928}
}
Kostenlos starten →